Once-daily oral obefazimod met the primary endpoint of clinical remission at 8 weeks in a highly refractory population of ulcerative colitis patients in two phase 3 trials.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/novel-agent-promising-refractory-ulcerative-colitis-2025a1000rc4?src=rss
Author :
Publish date : 2025-10-10 08:08:00
Copyright for syndicated content belongs to the linked Source.
